Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

New World Cutaneous or Mucocutaneous Leishmaniasis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sodium stibogluconate (Pentostam)

20 mg/kg IV every day for 20 or 28 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy proven new world cutaneous or mucocutaneous leishmania

Exclusion Criteria

* Prolonged QT
* Liver disease
* Pancreatitis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Schwartz, MD

Role: PRINCIPAL_INVESTIGATOR

University of CA at San Francisco

Kanade Shinkai, MD

Role: PRINCIPAL_INVESTIGATOR

University of CA at San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of CA at San Francisco Hospitals and Clinics

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCSF Infectious Diseases

Identifier Type: -

Identifier Source: org_study_id